Masoabi Sefojane: The Structural Invisibility of Bleeding Disorders in the Global South
Masoabi Sefojane, Geographic Expansion Lead, Africa and Asia Pacific at MicroHealth , shared a post on LinkedIn:
“The World Federation of Haemophilia identifies 37 percent of people with haemophilia globally.
In low-income countries? 11 percent.
In Africa? An estimated 88 percent remain undiagnosed.
Let me be direct: these numbers represent invisibility by design.
Not because diagnosis is impossible.
But because the systems to find people were built for certain geographies and certain people.
When my brother was 6 years old in Phuthaditjhaba, South Africa, he didn’t exist in any global haemophilia dataset.
He was bleeding, my family was desperate, but he was invisible.
No screening protocol would find him.
No registry would record him.
No system knew he existed.
This could have been my story if it wasn’t for my brothers.
Ask any bleeding disorder patient in the global south and you will hear similar stories and a pattern will also emerge.
Meanwhile, a child born with the same severe Hemophilia A in Amsterdam?
Known by age 1. Registered. Part of the data that shapes global priorities.
Same disease. Different visibility.
Here’s what the data shows: Africa, with 18 percent of the world’s population, represents less than 3 percent of identified haemophilia patients globally.
That’s not because Hemophilia is rare in Africa.
It’s because the systems designed to find Hemophilia were never designed to reach Africa.
The invisibility isn’t accidental.
It’s structural.
When a patient is invisible, they don’t exist in clinical trials.
They’re not counted in epidemiology.
They don’t influence treatment guidelines.
Their outcomes don’t matter because nobody’s measuring them.
The question we need to ask: Are we actually looking for these patients?
Or have we built systems that only find the ones in certain places?
Because that’s the real diagnosis gap.”
Other posts featuring Masoabi Sefojane on Hemostasis Today.
-
Jul 13, 2026, 11:25Luisa Müller: Advancing Anticoagulation Strategies for VITT at ISTH 2026
-
Jul 13, 2026, 10:49Joshua Zeidner: Advancing Menin Inhibitor Therapy in MD Education AML-ALL US Focus 2026
-
Jul 13, 2026, 10:25Flora Peyvandi: A Practical Approach to ALT Elevation After Gene Therapy at ISTH 2026
-
Jul 13, 2026, 10:02Jessica Garcia: Where Science and Community Come Together at ISTH 2026
-
Jul 13, 2026, 09:46Fabrice Cognasse: Is There Such a Thing as the Perfect Platelet Product?
-
Jul 13, 2026, 09:42Cancer-Associated Arterial Thromboembolism: Redefining the Thrombotic Burden in Oncology
-
Jul 13, 2026, 05:59Connecting and Collaborating at ISTH 2026 – NNHF
-
Jul 13, 2026, 05:58Lara Monica: Back at ISTH – Looking Forward to Science and Reconnections!
-
Jul 13, 2026, 05:57Barbara Adams Krolak: Exciting Updates From the ISTH 2026 Regulatory Session